世界のクラミジア感染症治療市場は2027年までに10％のCAGRで拡大し、128億2,150万ドルを超えると予想されています。クラミジアは、クラミジア・トラコマチによって引き起こされる性感染症（STI）です。クラミジアの治療法には抗生物質があります。性感染症の増加とクラミジアの有病率の増加がクラミジア感染症治療市場の成長を後押しします。さらに、性感染症に対する国民の意識の高まりと、性感染症に対する意識を広めるための政府の取り組みの強化が市場の成長を一層、促しています。米国疾病予防管理センター（CDC）によると、クラミジア感染症は米国の24歳以下の人々で最も有病率が高くなっています。さらに、無症候性の感染症も人々の間で非常に多くなっています。したがって、感染のリスクが高い25歳未満およびそれ以上の年齢のすべての性的に活発な女性における毎年のスクリーニングが推奨されます。
目次
TABLE OF CONTENTS
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Techniques
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Impact on Supply Chain
5.3.3. Regional Impact
5.3.4. Opportunity and Threat Analysis
6. GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS
6.1. Overview
6.2. Chlamydia trachomatis
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.3. Chlamydophila pneumoniae
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
7. GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.2. Oral
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
7.3. Injectable
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
7.4. Others
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
8. GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL
8.1. Overview
8.2. Hospital Pharmacy
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
8.3. Online Pharmacy
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
8.4. Retail Pharmacy
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
8.5. Others
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
9. GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET, BY REGION
9.1. Overview
9.2. North America
9.2.1. US
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. Italy
9.3.4. Spain
9.3.5. UK
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Rest of the World
9.5.1. Middle East
9.5.2. Africa
9.5.3. Latin America
10. COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Chlamydia Infection Treatment Market
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Chlamydia Infection Treatment Market
10.7. Key Developments and Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger &Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income,2020
10.8.2. Major Players R&D Expenditure,2020
11. COMPANY PROFILES
11.1. Merck & Co. Inc.
11.1.1. Company Overview
11.1.2. Products Offered
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Pfizer Inc
11.2.1. Company Overview
11.2.2. Products Offered
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. GlaxoSmithKline Plc
11.3.1. Company Overview
11.3.2. Products Offered
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. AstraZeneca
11.4.1. Company Overview
11.4.2. Products Offered
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Gilead Sciences Inc.
11.5.1. Company Overview
11.5.2. Products Offered
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Sanofi
11.6.1. Company Overview
11.6.2. Products Offered
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Teva Pharmaceuticals
11.7.1. Company Overview
11.7.2. Products Offered
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Sun Pharma
11.8.1. Company Overview
11.8.2. Products Offered
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Eli Lilly and Company
11.9.1. Company Overview
11.9.2. Products Offered
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Novartis
11.10.1. Company Overview
11.10.2. Products Offered
11.10.3. Financial Overview
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports
?
LIST OF TABLES
TABLE 1 GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET SYNOPSIS, 2018-2027
TABLE 2 GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET ESTIMATES &FORECAST, 2018-2027 (USD MILLION)
TABLE 3 GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET, BYCAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 4 GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 5 GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 6 NORTH AMERICA: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 7 NORTH AMERICA CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 8 NORTH AMERICA: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 9 US: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 10 US CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 11 US: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 12 CANADA: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 13 CANADA CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2027 (USD MILLION)
TABLE 14 CANADA: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 15 EUROPE: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 16 EUROPE: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 17 EUROPE: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 18 GERMANY: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 19 GERMANY: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 20 GERMANY: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 21 UK: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 22 UK: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 23 UK: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 24 FRANCE: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 25 FRANCE: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 26 FRANCE: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 27 ITALY: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 28 ITALY: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 29 ITALY: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 30 SPAIN: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 31 SPAIN: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 32 SPAIN: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 33 REST OF EUROPE: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 34 REST OF EUROPE: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 35 REST OF EUROPE: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 36 ASIA-PACIFIC: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 37 ASIA-PACIFIC: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 38 ASIA-PACIFIC: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 39 INDIA: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 40 INDIA: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 41 INDIA: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 42 CHINA: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 43 CHINA: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 44 CHINA: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 45 JAPAN: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 46 JAPAN: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 47 JAPAN: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 48 AUSTRALIA: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 49 AUSTRALIA: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 50 AUSTRALIA: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 51 SOUTH KOREA: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 52 SOUTH KOREA: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 53 SOUTH KOREA: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 54 REST OF ASIA-PACIFIC: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 55 REST OF ASIA-PACIFIC: CHLAMYDIA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 56 REST OF ASIA-PACIFIC: CHLAMYDIA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 57 REST OF THE WORLD: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 58 REST OF THE WORLD: CHLAMYDIA INFECTION TREATMENT MARKET, TECHNIQUE 2018-2027 (USD MILLION)
TABLE 59 REST OF THE WORLD: CHLAMYDIA INFECTION TREATMENT MARKET, END USER, 2018-2027 (USD MILLION)
TABLE 60 MIDDLE EAST: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 61 MIDDLE EAST: CHLAMYDIA INFECTION TREATMENT MARKET, TECHNIQUE 2018-2027 (USD MILLION)
TABLE 62 MIDDLE EAST: CHLAMYDIA INFECTION TREATMENT MARKET, END USER, 2018-2027 (USD MILLION)
TABLE 63 AFRICA: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 64 AFRICA: CHLAMYDIA INFECTION TREATMENT MARKET, TECHNIQUE 2018-2027 (USD MILLION)
TABLE 65 AFRICA: CHLAMYDIA INFECTION TREATMENT MARKET, END USER, 2018-2027 (USD MILLION)
TABLE 66 LATIN AMERICA: CHLAMYDIA INFECTION TREATMENT MARKET, BY CAUSATIVE ORGANISMS, 2018-2027 (USD MILLION)
TABLE 67 LATIN AMERICA: CHLAMYDIA INFECTION TREATMENT MARKET, TECHNIQUE 2018-2027 (USD MILLION)
TABLE 68 LATIN AMERICA: CHLAMYDIA INFECTION TREATMENT MARKET, END USER, 2018-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET
FIGURE 4 GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET SHARE, BY CAUSATIVE ORGANISMS, 2020(%)
FIGURE 5 GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2020(%)
FIGURE 6 GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET SHARE, BY DISTRIBUTION CHANNEL, 2020(%)
FIGURE 7 GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET SHARE, BY REGION, 2020(%)
FIGURE 8 NORTH AMERICA: CHLAMYDIA INFECTION TREATMENT MARKET SHARE, BY REGION, 2020 (%)
FIGURE 9 EUROPE: CHLAMYDIA INFECTION TREATMENT MARKET SHARE, BY REGION, 2020(%)
FIGURE 10 ASIA-PACIFIC: CHLAMYDIA INFECTION TREATMENT MARKET SHARE, BY REGION, 2020(%)
FIGURE 11 REST OF THE WORLD: CHLAMYDIA INFECTION TREATMENT MARKET SHARE, BY REGION, 2020(%)
FIGURE 12 GLOBAL CHLAMYDIA INFECTION TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020(%)
FIGURE 13 MERCK & CO. INC: KEY FINANCIALS
FIGURE 14 MERCK & CO. INC: SEGMENTAL REVENUE
FIGURE 15 MERCK & CO. INC: REGIONAL REVENUE
FIGURE 16 PFIZER INC: KEY FINANCIALS
FIGURE 17 PFIZER INC: SEGMENTAL REVENUE
FIGURE 18 PFIZER INC: REGIONAL REVENUE
FIGURE 19 GLAXOSMITHKLINE PLC: KEY FINANCIALS
FIGURE 20 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE
FIGURE 21 GLAXOSMITHKLINE PLC: REGIONAL REVENUE
FIGURE 22 ASTRAZENECA: KEY FINANCIALS
FIGURE 23 ASTRAZENECA: SEGMENTAL REVENUE
FIGURE 24 ASTRAZENECA: REGIONAL REVENUE
FIGURE 25 GILEAD SCIENCES INC.: KEY FINANCIALS
FIGURE 26 GILEAD SCIENCES INC.: SEGMENTAL REVENUE
FIGURE 27 GILEAD SCIENCES INC.: REGIONAL REVENUE
FIGURE 28 SANOFI: KEY FINANCIALS
FIGURE 29 SANOFI: SEGMENTAL REVENUE
FIGURE 30 SANOFI: REGIONAL REVENUE
FIGURE 31 TEVA PHARMACEUTICALS: KEY FINANCIALS
FIGURE 32 TEVA PHARMACEUTICALS: SEGMENTAL REVENUE
FIGURE 33 TEVA PHARMACEUTICALS: REGIONAL REVENUE
FIGURE 34 SUN PHARMA: KEY FINANCIALS
FIGURE 35 SUN PHARMA: SEGMENTAL REVENUE
FIGURE 36 SUN PHARMA: REGIONAL REVENUE
FIGURE 37 ELI LILLY AND COMPANY: KEY FINANCIALS
FIGURE 38 ELI LILLY AND COMPANY: SEGMENTAL REVENUE
FIGURE 39 ELI LILLY AND COMPANY: REGIONAL REVENUE
FIGURE 40 NOVARTIS: KEY FINANCIALS
FIGURE 41 NOVARTIS: SEGMENTAL REVENUE
FIGURE 42 NOVARTIS: REGIONAL REVENUE
